Endometriosis is a brutal condition, where tissue like the uterus lining grows where it shouldn’t from the ovaries to the fallopian tubes and even in the lungs. Causing a mass of pelvic pain, excruciating periods and infertility.
It affects 190 million women worldwide, costing Australia alone $9.7 billion annually, with current diagnosis leaning on invasive surgeries like laparoscopies, with an average seven-year wait.
Proteomics says its testing offers a non-invasive alternative, slashing delays and easing patient burden.
Proteomics International managing director Dr. Richard Lipscombe said: “This is an important collaboration as we bring PromarkerEndo to market in the coming months. Endometriosis is a complicated disease which affects millions of women and girls globally, and it is essential that our results are validated in multiple studies to add to the body of data on the test’s accuracy.”
The second and newer arm of the deal dives into “peritoneal fluid”, which sits close to endometriotic lesions. This fluid is a goldmine for biomarkers not easily spotted in blood, offering a shot at a test that not only detects endometriosis but details where it may be lurking.
The agreement hands Proteomics exclusive rights to commercialise any new intellectual property, jointly owned with its partners, with an option for full ownership on hitting milestones.
The 10-year licence can extend another decade or match any new patent’s life.
Proteomics’ Promarker platform underpins its broader testing portfolio, including PromarkerD for diabetic kidney disease and PromarkerEso for oesophageal cancer.
With endometriosis a major unmet need in healthcare, Proteomics’ push could potentially reshape outcomes for millions. The company is eyeing a slice of the multibillion-dollar diagnostics market, with PromarkerEndo expected to land in Australian in a matter of months.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
